Long-term Safety and Efficacy of Tamsulosin for the Treatment of Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia
Author:
Affiliation:
1. From the North Florida Research Institute, Inc., Gainesville, Florida, Department of Urology, University of California, Davis School of Medicine, Sacramento, California, and Division of Urology, University of Wisconsin, Madison, Wisconsin
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Urology
Reference14 articles.
1. The development of human benign prostatic hyperplasia with age;Berry;J Urol,1984
2. A second phase III multicenter placebo controlled study of 2 dosages of modified release tamsulosin in patients with symptoms of benign prostatic hyperplasia;Narayan;J Urol,1998
3. Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Tamsulosin Investigator Group;Lepor;Urology,1998
4. Long-term evaluation of tamsulosin in benign prostatic hyperplasia: placebo-controlled, double-blind extension of phase III trial. Tamsulosin Investigator Group;Lepor;Urology,1998
5. Tamsulosin, the first prostate-selective alpha1A-adrenoceptor antagonist. A meta-analysis of two randomized, placebo-controlled, multicentre studies in patients with benign prostatic obstruction (symptomatic BPH). European Tamsulosin Study Group;Chapple;Eur Urol,1996
Cited by 75 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Prevention of Benign Prostate Syndrome;Benign Prostate Syndrome;2023
2. Factors Affecting the Outcome of Medical Treatment in Cats with Obstructive Ureteral Stones Treated with Tamsulosin: 70 Cases (2018–2022);Veterinary Sciences;2022-10-16
3. Orthostatic blood pressure recovery in older males using alpha‐blockers for lower urinary tract symptoms, an explorative study in a urology outpatient clinic;Journal of Clinical Pharmacy and Therapeutics;2022-07
4. Prävention des Benignen Prostatasyndroms;Benignes Prostatasyndrom;2022
5. Cost analysis of alpha blocker treatments for benign prostatic hyperplasia in Medicare beneficiaries;Research in Social and Administrative Pharmacy;2021-06
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3